This conversation starts when co-host Jörn Schattenberg joins our EASL Congress 20224 preview. The episode itself focuses on the future of hepatology along with other MASLD abstracts and presentations.
This final conversation from #SLDThinkTank 2024 start with the question, “Next year?” Two key foci emerge: broadening the set of groups in the meeting and focusing more broadly on the concept of preventive hepatology.
Jeff Lazarus describes the meeting agenda and some of the anticipated outputs, after which other panelists discuss the broad range of issues this design produced.
SLD Think Tank 2024 co-hosts Jeff Lazarus and Jörn Schattenberg describe a highly innovative meeting design and participants Maja Thiele and Mike Betel sharing their reactions.
Patient advocates Jeff McIntyre (Global Liver Institute) and Mike Betel (Fatty Liver Alliance, Liver Action Network) join Louise Campbell and Roger Green to discuss GLI’s premier MASH patient event, now known as Global Fatty Livery Day.
This week’s vault episode looks back to last September, when Laurent Castera joined the Surfers to discuss different roles that NITs can play in MASH drug development and patient assessment.
This week’s vault exercise looks back to our coverage of The EASL Congress 2023, when the panel discusses the role of FIB-4 and other elements in the clinical care pathway.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
